Navigation Links
Allscripts Reports Third Quarter 2007 Results
Date:11/8/2007

Company Posts Record Sales and Revenue

CHICAGO, Nov. 8 /PRNewswire-FirstCall/ -- Allscripts, the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare, today announced results for the three and nine months ended September 30, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b)

Total revenue for the three months ended September 30, 2007 was $73.4 million, a record for the company, compared to $62.2 million for the same period last year. Revenue from software and related services for the three months ended September 30, 2007 was $59.0 million, compared to $49.5 million for the same period last year, increasing by 19.1%.

Gross margin percentage was 50.1% for the third quarter of 2007, compared to 49.1% during the third quarter of 2006.

Net income for the three months ended September 30, 2007 was $4.1 million, or $0.07 per diluted share, compared to net income of $3.3 million, or $0.06 per diluted share, for the same period last year. Reported net income for the three months ended September 30, 2007 and 2006 reflects deal-related amortization of $1.7 million and $1.9 million, respectively, or $0.03 per diluted share for both periods, net of tax, and total stock-based compensation of $0.9 million and $0.4 million, respectively, or $0.01 per diluted share for both reported periods, net of tax.

Non-GAAP adjusted earnings for the three months ended September 30, 2007 were $6.7 million, or $0.11 per diluted share, compared to non-GAAP adjusted earnings of $5.5 million, or $0.10 per diluted share for the same period last year. Please see "Non-GAAP Financial Measures" below for a discussion of non-GAAP adjusted earnings and earnings per share.

As of September 30, 2007, the Company had cash and marketable securities of $75.0 million.

56,191 53,048 55,500 50,081

Weighted average shares of common

stock outstanding used in

computing diluted net income per

share (c) 65,225 55,676 64,541 52,572

(a) Includes stock-based compensation of $247 and $0 for the three

months ended September 30, 2007 and 2006, respectively and $432 and

$0 for the nine months ended September 30, 2007 and 2006,

respectively.

(b) Includes stock-based compensation of $1,262 and $617 for the three

months ended September 30, 2007 and 2006, respectively and $2,358

and $1,440 for the nine months ended September 30, 2007 and 2006,

respectively.

(c) Weighted average diluted shares for the three and nine months ended

September 30, 2007 include 7,329 common shares related to the

Company's 3.5% Senior Convertible Notes. Such shares were

antidilutive for the three and nine months ended September 30, 2006.

Interest expense, net of tax, totaling $521 has been added back to

net income for the net income per diluted share calculation for the

three and nine months ended September 30, 2007.

Allscripts Healthcare Solutions, Inc.

Reconciliation of Non-GAAP Adjusted Earnings and Non-GAAP

Adjusted Earnings Per Share

(amounts in thousands, except per-share amounts)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Net Income $4,124 $3,262 $14,619 $7,412

Stock compensation expense (tax

effected at 40% for 2007 and

38% for 2006) 905 383 1,674 893

Deal-related amortization (tax

effected at 40% for 2007 and

38% for 2006) 1,654 1,888 4,745 4,772

Non-GAAP Adjusted Earnings $6,683 $5,533 $21,038 $13,077

Weighted average shares of

common stock outstanding used

in computing diluted non-GAAP

adjusted earnings per share 65,225 55,676 64,541 52,572

Non-GAAP Adjusted Earnings per

share - diluted $0.11 $0.10 $0.35 $0.25

"Allscripts made solid progress in the third quarter with record clinical software sales of $63.2 million, including two of the largest agreements in our history -- Columbia University Medical Center, one of the world's most prestigious academic medical centers, and Lahey Clinic, the nation's first multi-specialty group practice," said Glen Tullman, Chief Executive Officer of Allscripts. "Sales in our clinical software businesses grew 77 percent over last year, confirming both the acceleration in the market and Allscripts continuing leadership."

Total revenue for the nine months ended September 30, 2007 was $208.5 million, compared to $164.4 million for the same period last year. Revenue from software and related services for the nine months ended September 30, 2007 was $164.9 million, compared to $124.6 million for the same period last year, increasing by 32.4%.

Gross margin percentage was 50.1% for the first nine months of 2007, compared to 49.8% during the same period of 2006.

Net income for the nine months ended September 30, 2007 nearly doubled year-over-year to $14.6 million, or $0.25 per diluted share, compared to net income of $7.4 million, or $0.14 per diluted share, for the same period last year. Reported net income for the nine months ended September 30, 2007 and 2006 reflects deal-related amortization of $4.7 million, or $0.07 per diluted share, net of tax, and $4.8 million, or $0.09 per diluted share, net of tax, respectively, and total stock-based compensation of $1.7 million or $0.03 per diluted share, net of tax, and $0.9 million, or $0.02 per diluted share, net of tax, respectively. Non-GAAP adjusted earnings for the nine months ended September 30, 2007 were $21.0 million, or $0.35 per diluted share, compared to non-GAAP adjusted earnings of $13.1 million, or $0.25 per diluted share for the same period last year.

Outlook

Allscripts has updated its revenue target for the full year 2007 to a range of $286 million to $288 million. This target represents annualized growth in total revenue of approximately 25%, and is reflective of approximately 30% annualized growth from software and related services. The Company also updated its GAAP earnings per diluted share outlook to a range of $0.34 to $0.35, representing annualized growth of approximately 55%, and its Non-GAAP adjusted earnings per diluted share outlook to a range of $0.48 to $0.49. Non-GAAP adjusted earnings contemplates the add-back of approximately $6.4 million, or $0.10 per diluted share, of deal-related amortization and approximately $3.0 million, or $0.04 per diluted share, of stock-based compensation, both net of tax.

The Company also provided its outlook for 2008 with annualized growth in total revenue of approximately 20% to 25%, which is reflective of approximately 25% to 30% in annualized growth from software and related services. This target represents annualized growth in GAAP earnings per diluted share of 40% to 50%. Annualized growth in Non-GAAP adjusted earnings per diluted share is expected to be 40% to 45%, which contemplates approximately $6.6 million or $0.10 per diluted share of deal-related amortization, and approximately $6.0 million, or $0.09 per diluted share of stock-based compensation, both net of tax.

Allscripts will conduct a conference call on Thursday, November 8, 2007 at 4:30 PM Eastern Standard Time to discuss the Company's earnings and other information. The conference call can be accessed by dialing 1-888-644-5594 and requesting the Allscripts earnings call, or via the Internet at http://www.allscripts.com. A recording of the conference call will be available for a period of two weeks following the call at http://www.allscripts.com or by calling 1-800-642-1687, ID # 21783504.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this press release non-GAAP net income (and related per share amounts), which is a non-GAAP financial measure under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Non-GAAP net income consists of GAAP net income, excluding acquisition-related amortization and stock-based compensation expense under SFAS No. 123R, in each case net of any related tax benefit.

-- Acquisition-Related Amortization. Acquisition-related amortization

expense is a non-cash expense arising from the acquisition of

intangible assets in connection with acquisitions or investments.

Allscripts excludes acquisition-related amortization expense from

non-GAAP net income because it believes (i) the amount of such expenses

in any specific period may not directly correlate to the underlying

performance of Allscripts business operations and (ii) such expenses

can vary significantly between periods as a result of new acquisitions

and full amortization of previously acquired intangible assets.

Investors should note that the use of these intangible assets

contributed to revenue in the periods presented and will contribute to

future revenue generation and should also note that such expense will

recur in future periods.

-- Stock-Based Compensation Expense. Stock-based compensation expense is a

non-cash expense arising from the grant of stock awards to employees.

Allscripts excludes stock-based compensation expense from non-GAAP net

income because it believes (i) the amount of such expenses in any

specific period may not directly correlate to the underlying

performance of Allscripts business operations and (ii) such expenses

can vary significantly between periods as a result of the timing of

grants of new stock-based awards, including grants in connection with

acquisitions. Investors should note that stock-based compensation is a

key incentive offered to employees whose efforts contributed to the

operating results in the periods presented and are expected to

contribute to operating results in future periods and should also note

that such expense will recur in future periods.

Management also believes that non-GAAP net income (and related per share amounts) provides useful supplemental information to management and investors regarding the underlying performance of the Company's business operations and facilitates comparisons to our historical operating results. Management also uses this information internally for forecasting and budgeting as it believes that the measure is indicative of the Company's core operating results. Note however, that non-GAAP net income is a performance measure only, and it does not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

About Allscripts

Allscripts (Nasdaq: MDRX) is the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare. The Company's business units provide unique solutions that inform, connect and transform healthcare. Allscripts award-winning software applications include Electronic Health Records, practice management, e-prescribing, document imaging, emergency department, and care management solutions, all offered through the Company's Clinical Solutions units. Additionally, Allscripts provides clinical product education and connectivity solutions for physicians and patients through its Physicians Interactive(TM) unit, and medication fulfillment services through its Medication Services unit. To learn more, visit Allscripts on the Web at http://www.allscripts.com.

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, actual results may vary materially from those anticipated by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry; possible regulation of the Company's software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers; our ability to obtain, use or successfully integrate third-party licensed technology; breach of our security by third parties; and the risk factors detailed from time to time in our reports filed with the Securities and Exchange Commission, including our 2006 Annual Report on Form 10-K available through the Web site maintained by the Securities and Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

Allscripts Healthcare Solutions, Inc.

Condensed Consolidated Balance Sheets

(amounts in thousands)

(Unaudited)

Sept. 30, Dec. 31,

Assets 2007 2006

Current assets:

Cash and cash equivalents $31,968 $42,461

Marketable securities 28,384 14,553

Accounts receivable, net 81,225 55,579

Deferred taxes, net 24,391 27,437

Inventories 4,370 3,247

Prepaid expenses and other current assets 16,920 10,620

Total current assets 187,258 153,897

Long-term marketable securities 14,673 26,024

Fixed assets, net 16,662 14,094

Software development costs, net 19,720 12,285

Intangible assets, net 74,717 78,050

Goodwill 181,397 188,261

Other assets 4,552 4,999

Total assets $498,979 $477,610

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $14,695 $9,294

Accrued liabilities 19,929 26,546

Deferred revenue 41,084 35,549

Current portion of long-term debt 274 258

Total current liabilities 75,982 71,647

Long-term debt 85,234 85,441

Deferred income taxes 3,266 3,915

Other liabilities 2,207 357

Total liabilities 166,689 161,360

Stockholders' equity 332,290 316,250

Total liabilities and stockholders' equity $498,979 $477,610

Allscripts Healthcare Solutions, Inc.

Condensed Consolidated Statements of Operations

(amounts in thousands, except per-share amounts)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Revenue:

Software and related services $58,985 $49,534 $164,906 $124,593

Prepackaged medications 10,904 10,438 32,072 32,456

Information services 3,555 2,219 11,529 7,360

Total revenue 73,444 62,191 208,507 164,409

Cost of revenue:

Software and related services 25,017 21,631 70,196 51,616

Prepackaged medications 9,223 8,802 26,672 26,844

Information services 2,408 1,202 7,099 3,996

Total cost of revenue (a) 36,648 31,635 103,967 82,456

Gross profit 36,796 30,556 104,540 81,953

Operating expenses:

Selling, general and

administrative expenses (b) 27,173 21,947 74,972 61,877

Amortization of intangibles 2,757 3,045 7,909 7,696

Income from operations 6,866 5,564 21,659 12,380

Interest expense (927) (940) (2,790) (2,775)

Interest income and other, net 934 649 3,077 2,361

Gain on sale of equity investment - - 2,392 -

Income before income taxes 6,873 5,273 24,338 11,966

Income taxes (2,749) (2,011) (9,719) (4,554)

Net income $4,124 $3,262 $14,619 $7,412

Net income per share - basic $0.07 $0.06 $0.26 $0.15

Net income per share - diluted $0.07 $0.06 $0.25 $0.14

Weighted average shares of common

stock outstanding used in

computing basic net income per

share
'/>"/>

SOURCE Allscripts Healthcare Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
2. West Penn Allegheny Health System Selects Electronic Health Record From Allscripts
3. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
4. Allscripts Featured in Microsoft HealthVault Worldwide Launch
5. Lakeside Systems Selects Allscripts Electronic Health Record for 100 Physicians
6. Allscripts to Announce Third Quarter 2007 Results on November 8th
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... “Tomorrow Trump Goes ... Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes To ... do as much as she can for this country. , Nancy attributes her patriotic ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men ... a higher risk of serious health problems, such as cardiovascular illness, according to ... Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the correlation ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health management, announces today a strategic relationship with CitiusTech, a leading healthcare ... engine that offers advanced Clinical Quality Measures (CQM) computation capabilities (as a ...
(Date:12/6/2016)... ... December 06, 2016 , ... CarriersEdge, providers of online ... new suite of Driver Wellness courses. Offered in three modules, the courses can be ... so fleets can educate drivers about how to stay healthy on the road. , ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... NEW YORK , Dec. 6, 2016 ... atomic nucleus. Radioisotopes are produced either by using nuclear ... energy in the form of alpha, beta or gamma ... thus emitted are used in Nuclear medicine, specifically in ... to provide diagnostic information about a human body,s functioning. ...
(Date:12/6/2016)... 6, 2016 Human Vaccines Market: Scope ... wise and country wise analysis of the human ... of human vaccines products, raw material suppliers, vaccine ... the market. The report provides qualitative and ... Qualitative analysis comprises market dynamics, trends, product overview, ...
(Date:12/6/2016)... BOLTON, Miss. , Dec. 6, 2016 ... and rescue personnel in a simulated mass casualty event ... Mississippi . The technology debuted before an audience ... Bryant and representatives from Homeland Security, Federal Law ... Telemedical Drone Project, known as HiRO (Health Integrated Rescue ...
Breaking Medicine Technology: